Entero Therapeutics, Inc. (ENTO)
NASDAQ: ENTO · Real-Time Price · USD
0.493
-0.032 (-6.04%)
Feb 21, 2025, 4:00 PM EST - Market closed
Entero Therapeutics Employees
Entero Therapeutics had 9 employees as of December 31, 2023. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
-$1,127,763
Market Cap
2.35M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ENTO News
- 8 days ago - Entero Therapeutics Appoints Richard Paolone as CEO - GlobeNewsWire
- 15 days ago - Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members - GlobeNewsWire
- 3 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - Accesswire
- 3 months ago - ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO - Business Wire
- 3 months ago - Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company - GlobeNewsWire
- 4 months ago - Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board - Business Wire
- 6 months ago - Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - GlobeNewsWire
- 7 months ago - Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program - GlobeNewsWire